27.11.2017 22:00:00
|
Amgen To Present At The Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
THOUSAND OAKS, Calif., Nov. 27, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference on Thursday, Nov. 30, 2017, in Boston, beginning at 9:30 a.m. ET. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand Oaks
Kristen Davis, 805-447-3008 (media)
Kristen Neese, 805-313-8267 (media)
Arvind Sood, 805-447-1060 (investors)
View original content with multimedia:http://www.prnewswire.com/news-releases/amgen-to-present-at-the-evercore-isi-2017-biopharma-catalystdeep-dive-conference-300562058.html
SOURCE Amgen
![](https://images.finanzen.at/images/unsortiert/wertpapierdepot-absichern-aktienchart-boerse-750493204-260.jpg)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Amgen Inc.mehr Nachrichten
17.02.25 |
Dow Jones 30 Industrial-Papier Amgen-Aktie: So viel Gewinn hätte ein Amgen-Investment von vor 5 Jahren eingefahren (finanzen.at) | |
14.02.25 |
Minuszeichen in New York: Dow Jones schlussendlich leichter (finanzen.at) | |
14.02.25 |
Verluste in New York: Dow Jones präsentiert sich am Nachmittag schwächer (finanzen.at) | |
14.02.25 |
Freitagshandel in New York: Dow Jones verliert mittags (finanzen.at) | |
14.02.25 |
Minuszeichen in New York: Dow Jones verliert zum Start des Freitagshandels (finanzen.at) | |
11.02.25 |
Schwache Performance in New York: Dow Jones zum Handelsstart in Rot (finanzen.at) | |
10.02.25 |
Dow Jones 30 Industrial-Titel Amgen-Aktie: So viel hätten Anleger mit einem Investment in Amgen von vor 3 Jahren verdient (finanzen.at) | |
05.02.25 |
Börse New York in Grün: NASDAQ 100 zum Ende des Mittwochshandels mit Kursplus (finanzen.at) |
Analysen zu Amgen Inc.mehr Analysen
Aktien in diesem Artikel
Amgen Inc. | 279,40 | 0,81% |
|